Kondoh H, Niwa K, Itoh N, Murase T, Morishita S, Imai A, Tamaya T
Dept. of Obstetrics and Gynecology, University of Gifu School of Medicine, Japan.
Gan To Kagaku Ryoho. 1996 Jun;23(7):893-7.
Using flow cytometry, we examined the correlations between the tumor stage and the cell cycle in subjects with advanced cervical squamous cell carcinoma as well as between the changes of cell cycle caused by 5-FU and their prognoses. Before 5-FU treatment, 75.9 +/- 9.6% of the patients were at G1 phase, 16.8 +/- 3.9% at S and 7.3 +/- 4.5% at G2/M. The change of cell cycle was not accompanied by the progression of tumor stage. Sixteen patients received oral 5-FU (300 mg/day) for at least 2 weeks before operation. In the patients at stage I, the cell cycle was not changed even after 5-FU treatment. They have been cancer-free for 3 postoperative years. While early recurrence was found in 4 of 5 cases at stage II or III showing progression at G1, all 6 cases who had regressed or remained unchanged at G1 were free from recurrence (p = 0.0152). These results suggested that the cell cycle is not necessarily correlated with the progression of tumor stage in patients with this kind of carcinoma, and that the change of cell cycle due to preoperative oral 5-FU could be a predictive indicator for their prognoses. Especially for those with poor prognoses who had shown progression at G1, more potent adjuvant chemotherapy should be planned.
我们运用流式细胞术，研究了晚期宫颈鳞状细胞癌患者的肿瘤分期与细胞周期之间的相关性，以及5-氟尿嘧啶（5-FU）引起的细胞周期变化与其预后的相关性。在5-FU治疗前，75.9±9.6%的患者处于G1期，16.8±3.9%处于S期，7.3±4.5%处于G2/M期。细胞周期的变化并未伴随肿瘤分期的进展。16例患者在手术前口服5-FU（300mg/天）至少2周。在I期患者中，即使经过5-FU治疗，细胞周期也未发生变化。他们术后3年无癌。而在II期或III期的5例患者中，有4例在G1期出现进展并早期复发，所有6例在G1期出现消退或未改变状态的患者均无复发（p = 0.0152）。这些结果表明，对于这类癌症患者，细胞周期不一定与肿瘤分期的进展相关，术前口服5-FU引起的细胞周期变化可能是其预后的一个预测指标。特别是对于那些在G1期出现进展、预后较差的患者，应制定更有效的辅助化疗方案。
